SUPN | tickerfilter.com

Fundamental analysis

75%

Profitability 77%

Dept financing 35%

Liquidity 74%

Performance 85%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.21%

1 Month

5.01%

3 Months

14.23%

6 Months

17.57%

1 Year

67.98%

2 Year

74.85%

Key data

Stock price

$53.87

P/E Ratio

0.00

DAY RANGE

$52.27 - $54.24

EPS

-$0.33

52 WEEK RANGE

$29.16 - $59.68

52 WEEK CHANGE

$64.04

MARKET CAP

2.680 B

YIELD

N/A

SHARES OUTSTANDING

57.339 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-07-2025

BETA

0.73

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,034,901

AVERAGE 30 VOLUME

$879,981

Company detail

CEO: Jack A. Khattar
Region: US
Website: supernus.com
Employees: 580
IPO year: 2012

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Supernus Pharmaceuticals, Inc. focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the. treatment of epilepsy, as well as for the prophylaxis of migraine headache. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors.

SUPN - SUPERNUS PHARMACEUTICALS, INC.